Loreen Mershimer is a accomplished leader with over 30 years of pharmaceutical industry experience. She has served
as an Independent Management Consultant, and is a retired Corporate Vice President, Abbott Laboratories with
experience in the hospital, pharmaceutical and international markets of Abbott. In her previous roles as VP
Integrated Healthcare Marketing & Policy, VP Hospital Pharmaceuticals and VP Hospital Business Sector, she was
responsible for leading dramatic and consistent growth across multiple businesses. During her tenure she lead
businesses through times of transition and drove excellence across commercial, manufacturing and R&D platforms. Ms.
Mershimer also represented Abbott by serving on the Board of Kidney Care Partners and was responsible for the very
successful introduction of Zemplar® in the treatment of secondary hyperparathyroidism and development of drugs in
the Renal business for Abbott. Ms. Mershimer received an MBA from Northwestern University, Kellogg Graduate School
of Management and a BA in Economics from Northwestern University.
Hector F. DeLuca, is a co-founder of Deltanoid Pharmaceuticals, Inc. and is recognized as a world leader in vitamin
D chemistry, biochemistry and medicine, and has nearly 820 filed and active patents on his technologies. The
majority of commercially-developed vitamin D analogs have originated in Professor DeLuca’s university lab.
Prior to establishing Deltanoid, Dr. DeLuca was involved in the development of eight drugs marketed worldwide with
over $10 billion in worldwide sales, including Alfarol®, Zemplar®, Rocaltrol®, Hectorol® and several
others. Dr. DeLuca has been a successful entrepreneur involved in the creation of the publicly held pharmaceutical
firm Bone Care International (NASDAQ:BCII) that was later acquired by Genzyme/Sanofi. He also was a founder of
Tetrionics, sold to SAFC. He also serves on the board of Kegonsa Capital Partners. Because of his expertise in the
field of vitamin D, Dr. DeLuca has developed contacts with many major pharmaceutical companies world-wide, and has
served as a consultant to many firms. Professor DeLuca was a faculty member in the Department of Biochemistry for
over 50 years, and served for 30 years as Chairman of that department. He continues to maintain an active research
program as an Emeritus Professor. He received his PhD in biochemistry from the University of Wisconsin-Madison, and
honorary degrees of medicine from the University of Colorado, the Medical College of Wisconsin, the Karolinska
Institute, Stockholm, and Queen’s University of Canada.
Margaret Clagett-Dame is a co-founder of Deltanoid Pharmaceuticals, Inc. and is known for her considerable
experience in both vitamin A and vitamin D, and has over 400 patents filed and active. Dr. Clagett-Dame also brings
experience in the pharmaceutical industry with one of the top 10 pharmaceutical companies in the U.S. She joined the
faculty at the University of Wisconsin-Madison in 1989, and currently holds a joint appointment at the rank of
Professor in the Department of Biochemistry, College of Agricultural and Life Sciences; and in the Pharmaceutical
Sciences Division in the School of Pharmacy. She obtained her MS in Nutrition from the Pennsylvania State University
and a PhD in Biochemistry from the University of Wisconsin-Madison.
Lori Plum brings over 15 years of experience in vitamin A and vitamin D research, and has worked in the University
laboratories of both Drs. Clagett-Dame and DeLuca. She has over 400 filed and active patents to her credit. Dr. Plum
attended North Dakota State University-Fargo where she received her BS in Nutrition and received her PhD in
Nutritional Sciences from the University of Wisconsin-Madison.
Linda Leikness brings over 20 years of management experience in entrepreneurial environments and biotechnology to
Deltanoid. Prior to joining Deltanoid, Ms. Leikness worked as Chief Financial Officer and Treasurer for PanVera
Corporation, sold to Life Technologies/Thermo Fisher Scientific (NASDAQ: TMO), and also worked as Chief Financial
Officer for Pleasant Company/American Girl, which was acquired by Mattel (NYSE:MAT). Ms. Leikness received her BA in
Accounting from the University of Wisconsin- Milwaukee and is a Certified Public Accountant and Global Certified